No Data
Beijing Konruns Pharmaceutical (603590.SH): The first subject has been enrolled in the Phase II clinical study of KC1036.
Beijing Konruns Pharmaceutical (603590.SH) announced that the KC1036 tablets (abbreviated as "KC1...") that the company developed independently...
Kangchen Pharmaceutical: Kangchen Pharmaceutical 2024 Annual Results Forecast
Kangchen Pharmaceutical 2024 Annual Results Forecast
Beijing Konruns Pharmaceutical (603590.SH): It is expected that the net income in 2024 will decrease by 63% to 73% compared to the previous year.
On January 23, Gelonghui reported that Beijing Konruns Pharmaceutical (603590.SH) announced that, 1. According to preliminary calculations by the finance department, it is expected that the net income attributable to the owners of the parent company for the year 2024 will be between 40 million yuan and 55 million yuan, a decrease of 95.4507 million yuan to 110.4507 million yuan compared to the same period last year (statutory disclosed data), representing a year-on-year decrease of 63% to 73%. 2. It is expected that the net income attributable to the owners of the parent company after deducting non-recurring gains and losses for the year 2024 will be between 30 million yuan and 45 million yuan.
Beijing Konruns Pharmaceutical (603590.SH): The "Construction project for a production base of 500 kg of Anti-tumor Active Pharmaceutical Ingredient" is proposed to be postponed to December 2026.
On December 16, Gelonghui reported that Beijing Konruns Pharmaceutical (603590.SH) announced that, based on the current progress of the "annual production of 500 kg Active Pharmaceutical Ingredient production base construction project," the company plans to extend the expected time for the project to become operational to December 2026, provided that there are no changes in the use of raised funds and investment scale.
Kangchen Pharmaceutical\'s 2024 Third Quarter Report